JP2024517788A - Ｍｐｎｓｔの処置のための化合物及び組成物 - Google Patents

Ｍｐｎｓｔの処置のための化合物及び組成物 Download PDF

Info

Publication number
JP2024517788A
JP2024517788A JP2023567063A JP2023567063A JP2024517788A JP 2024517788 A JP2024517788 A JP 2024517788A JP 2023567063 A JP2023567063 A JP 2023567063A JP 2023567063 A JP2023567063 A JP 2023567063A JP 2024517788 A JP2024517788 A JP 2024517788A
Authority
JP
Japan
Prior art keywords
day
amino
mpnst
inhibitor
cdk4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023567063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517788A5 (https=
Inventor
ハオ，ファイシャン
イー． ムーディー，スーザン
プラティラス，クリスチャン
ワン，ジアワン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of JP2024517788A publication Critical patent/JP2024517788A/ja
Publication of JP2024517788A5 publication Critical patent/JP2024517788A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023567063A 2021-05-05 2022-04-28 Ｍｐｎｓｔの処置のための化合物及び組成物 Pending JP2024517788A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163184422P 2021-05-05 2021-05-05
US63/184,422 2021-05-05
PCT/IB2022/053970 WO2022234409A1 (en) 2021-05-05 2022-04-28 Compounds and compositions for the treatment of mpnst

Publications (2)

Publication Number Publication Date
JP2024517788A true JP2024517788A (ja) 2024-04-23
JP2024517788A5 JP2024517788A5 (https=) 2025-05-07

Family

ID=81598046

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023567063A Pending JP2024517788A (ja) 2021-05-05 2022-04-28 Ｍｐｎｓｔの処置のための化合物及び組成物

Country Status (6)

Country Link
US (1) US20240238284A1 (https=)
EP (1) EP4333847A1 (https=)
JP (1) JP2024517788A (https=)
CN (1) CN117177752A (https=)
TW (1) TW202308631A (https=)
WO (1) WO2022234409A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025510572A (ja) 2022-03-08 2025-04-15 レボリューション メディシンズ インコーポレイテッド 免疫不応性肺癌を治療するための方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1761528T1 (sl) 2004-06-11 2008-06-30 Japan Tobacco Inc 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2H-pirido(2,3-D)pirimidinski derivati in sorodne spojine za zdravljenje raka
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
EP4302834A3 (en) 2016-07-12 2024-07-17 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
EP3923941B1 (en) * 2019-02-12 2025-12-03 Novartis AG Pharmaceutical combination comprising tno155 and ribociclib

Also Published As

Publication number Publication date
WO2022234409A1 (en) 2022-11-10
CN117177752A (zh) 2023-12-05
US20240238284A1 (en) 2024-07-18
EP4333847A1 (en) 2024-03-13
TW202308631A (zh) 2023-03-01

Similar Documents

Publication Publication Date Title
JP7493521B2 (ja) Ｔｎｏ１５５及びリボシクリブを含む医薬組合せ
JP7572958B2 (ja) Ｔｎｏ１５５及びｋｒａｓｇ１２ｃ阻害剤を含む医薬組合せ
EP3442529B1 (en) Combination therapy with notch and cdk4/6 inhibitors for the treatment of lung cancer
JP7278331B2 (ja) がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法
AU2021267213B2 (en) Pharmaceutical combination comprising TNO155 and nazartinib
JP2024517788A (ja) Ｍｐｎｓｔの処置のための化合物及び組成物
TW202308641A (zh) 用於治療癌症之方法及包含cdk抑制劑之給藥方案
CN106999485B (zh) 抗肺鳞癌的喹啉衍生物
RU2813111C2 (ru) Фармацевтическая комбинация, содержащая tno155 и рибоциклиб
HK40110657A (zh) 用於治疗癌症的cdk4抑制剂
HK40060474A (en) Pharmaceutical combination comprising tno155 and ribociclib
HK40004472B (en) Combination therapy with notch and cdk4/6 inhibitors for the treatment of lung cancer
HK40004472A (en) Combination therapy with notch and cdk4/6 inhibitors for the treatment of lung cancer
HK40004471A (en) Combination therapy with notch and pi3k/mtor inhibitors for use in treating ovarian cancer
HK40004471B (en) Combination therapy with notch and pi3k/mtor inhibitors for use in treating ovarian cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250422

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250422